The state of Connecticut along with 35 other states and the District of Columbia has reached a $36.5 million settlement with CVS Pharmacy resolving allegations that CVS knowingly submitted or caused to be submitted false claims to the Medicaid program related to the dispensing of insulin pens.
Connecticut Attorney General William Tong announced the settlement on Monday. The portion of the multi-state settlement attributable to Connecticut Medicaid is $1,00 million, of which the State only share is $633,913.
Tong said “over a decade, CVS over-billed our public healthcare programs for huge quantities of insulin pens, filling refills too early, too often, and too many."
"In coordination with states across the country and our federal law enforcement partners, we are holding CVS accountable," Tong said in a statement. "We will continue to act aggressively to protect taxpayer dollars and the integrity of our healthcare programs."
The settlement resolves claims that between 2010 through 2020, CVS violated the False Claims Act in connection with its billing and dispensing of insulin pens to patients enrolled in government healthcare programs including Medicare and Medicaid. The settlement addresses claims that CVS improperly requested and received program reimbursement for premature refills, dispensed more insulin pens than patients needed according to their prescriptions, and falsely under-reported the days-of-supply of insulin that its pharmacies dispensed.
Under the terms of...
HARTFORD, CT — Connecticut and a group of other states have reached a $35 million settlement with CVS Pharmacy, resolving allegations that CVS knowingly submitted or caused to be submitted false c...